Neuland Laboratories Ltd.

NSE: NEULANDLAB | BSE: 524558 | ISIN: INE794A01010 | Industry: Pharmaceuticals
| Falling Comet
11230.0000 166.00 (1.50%)
NSE May 29, 2025 15:31 PM
Volume: 65,689
 

11230.00
1.50%
HDFC Securities
Re-iterate BUY with a TP of Rs 1,000 (16x on FY20E EPS). Ahead of expectations, Neuland Labs (NLL) ended the year with improved business performance. Top line grew 13.2% YoY/31.5% QoQ to Rs 1.6bn, with significant jump seen in Ciprofloxacin and Levetiracetam revenues during this quarter. EBITDA declined 34%YoY to Rs 188mn. However, sequential growth of 105% was encouraging. EBITDA margin stood at 11.7% (down 838bps YoY, up 420bps QoQ and 170bps ahead of expectation). Reported PAT after merging with NHSPL and NPRPL, came in at Rs 81mn in 4QFY18.
Neuland Laboratories Ltd. is trading below all available SMAs
More from Neuland Laboratories Ltd.
Recommended